20 reports of this reaction
3.5% of all GLYBURIDE AND METFORMIN HYDROCHLORIDE reports
#2 most reported adverse reaction
HYPOGLYCAEMIA is the #2 most commonly reported adverse reaction for GLYBURIDE AND METFORMIN HYDROCHLORIDE, manufactured by Aurobindo Pharma Limited. There are 20 FDA adverse event reports linking GLYBURIDE AND METFORMIN HYDROCHLORIDE to HYPOGLYCAEMIA. This represents approximately 3.5% of all 579 adverse event reports for this drug.
Patients taking GLYBURIDE AND METFORMIN HYDROCHLORIDE who experience hypoglycaemia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
HYPOGLYCAEMIA is moderately reported among GLYBURIDE AND METFORMIN HYDROCHLORIDE users, representing a notable but not dominant share of adverse events.
In addition to hypoglycaemia, the following adverse reactions have been reported for GLYBURIDE AND METFORMIN HYDROCHLORIDE:
The following drugs have also been linked to hypoglycaemia in FDA adverse event reports:
HYPOGLYCAEMIA has been reported as an adverse event in 20 FDA reports for GLYBURIDE AND METFORMIN HYDROCHLORIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
HYPOGLYCAEMIA accounts for approximately 3.5% of all adverse event reports for GLYBURIDE AND METFORMIN HYDROCHLORIDE, making it one of the most commonly reported side effect.
If you experience hypoglycaemia while taking GLYBURIDE AND METFORMIN HYDROCHLORIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.